FDA’s Wayback Machine: Clinical Investigator Disqualifications Could Trigger Wide-Ranging Audits
This article was originally published in The Pink Sheet Daily
Executive Summary
Any clinical trial that an FDA-disqualified investigator was involved in may be subject to scrutiny, the agency says in explaining a final rule.
You may also be interested in...
FDA Will Revise Investigator Disqualification Regs In Response To GAO Report
The agency will revise its regulations to prevent clinical investigators who are disqualified from running trials for one product type to continue leading studies for other FDA-regulated categories.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.